Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 2Liposarcoma 2Leiomyosarcoma 2Sarcoma, Ewing 1Neoplasm Metastasis 1Liposarcoma, Myxoid 1

Interventions

Docetaxel 3pazopanib 2Trabectedin 2Doxorubicin 2toripalimab 1temsirolimus 1sapanisertib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Sunitinib 1Specimen Handling 1Radiotherapy 1Nivolumab 1Methotrexate 1Imatinib Mesylate 1Ifosfamide 1HhAntag691 1Gemcitabine 1Epirubicin 1Dacarbazine 1Cisplatin 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leiomyosarcoma × Trabectedin × Clear all
NCT02275286 2023-05-31

TRASTS

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Recruiting
199 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Liposarcoma, Myxoid

NCT03074318 2022-04-29

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
35 enrolled 21 charts
Sarcoma

Leiomyosarcoma, Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡